Google Finance Crtx
Cortexyme (CRTX) was a clinical-stage biopharmaceutical company focused on developing therapeutics to treat degenerative diseases, particularly Alzheimer’s disease. The company’s primary focus was on targeting Porphyromonas gingivalis, a bacterium associated with periodontal disease, and its role in Alzheimer’s pathogenesis.